Skip to content
Study details
Enrolling now

Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy

National Institute of Neurological Disorders and Stroke (NINDS)
NCT IDNCT02531880ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

40

Study length

about 1.6 years

Ages

18–60

Locations

1 site in MD

What this study is about

Researchers are testing if a drug called mangafodipir can be safely used to show areas affected by epilepsy on an MRI. The trial will involve adults with epilepsy who have not responded to medication, and it will last for about 590 days.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Mangafodipir

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

mangafodipir

Endpoints

Primary: evaluation of the utility of MEMRI and/or DCE-MRI in identifying focal BBBD in the seizure onset zone identified by standard clinical, EEG, and imaging studies, and the homologous contralateral region.

Body systems

Neurology